| Zymeworks Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20160083480 | Bispecific HER2 and HER3 Antigen Binding Constructs - Described herein are isolated bi-specific antigen binding constructs, e.g., antibodies. The bi-specific antigen binding constructs include two antigen binding polypeptide constructs, e.g., a Fab and an scFv. The first antigen-binding polypeptide construct monovalently and specifically binds to extracellular domain 4 (ECD4) of HER2 (human epidermal growth factor receptor 2); the second antigen-binding polypeptide construct monovalently and specifically binds to an extracellular domain (ECD) of HER3 (human epidermal growth factor receptor 3). One antigen binding polypeptide construct is a Fab format and the other antigen binding polypeptide construct is an scFv format. The bi-specific antigen binding constructs includes an Fc having two Fc polypeptides each having a CH3 domain for dimerization. Each Fc polypeptide is linked to the C-terminus of one of the antigen binding polypeptide constructs with or without a linker. | 03-24-2016 |
| 20140200331 | Engineered Immunoglobulin Heavy Chain-Light Chain Pairs And Uses Thereof - The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the C | 07-17-2014 |
| 20140154253 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs - Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3. | 06-05-2014 |
| 20140072581 | Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains - Disclosed herein is an isolated immunoglobulin construct comprising a first monomeric polypeptide comprising a first single chain Fv polypeptide connected to a first constant domain polypeptide; and a second monomeric polypeptide comprising a second single chain Fv polypeptide, connected to a second constant domain polypeptide; each said constant domain polypeptide comprising at least one each of a CL domain, a CH1 domain, a CH2 domain and a CH3 domain or fragments, variants or derivatives thereof; and wherein said first and second constant domain polypeptide form a Fc region. | 03-13-2014 |
| 20130245963 | SIMPLIFYING RESIDUE RELATIONSHIPS IN PROTEIN DESIGN - The invention provides a method of determining changes in a first set of residues r | 09-19-2013 |
| 20130238299 | SYSTEM FOR MOLECULAR PACKING CALCULATIONS - The invention provides a computer implemented method of quantifying the quality of packing for a residue comprising one or more residue atoms in a first protein in a first conformation, the method comprising: (a) calculating one or more close contact potentials based on a distance between the one or more residue atoms and one or more environment atoms, (b) calculating a contact area of the one or more residue atoms that is exposed to the one or more environment atoms and (c) calculating a close contact surface density (CCSD) by dividing the sum of the one or more close contact potentials by the contact area. | 09-12-2013 |
| 20130195849 | Stable Heterodimeric Antibody Design with Mutations in the Fc Domain - The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics. | 08-01-2013 |
| 20130108623 | Antibodies with Enhanced or Suppressed Effector Function | 05-02-2013 |
| 20130089541 | Antibodies with Enhanced or Suppressed Effector Function - Rationally designed antibodies and polypeptides that comprise multiple Fc region amino acid substitutions that synergistically provide enhanced selectivity and binding affinity to a target Fc receptor are provided. The polypeptides are mutated at multiple positions to make them more effective when incorporated in antibody therapeutics than those having wild-type Fc components. | 04-11-2013 |
| 20130013631 | DENSITY BASED CLUSTERING FOR MULTIDIMENSIONAL DATA - A new density based clustering method for clustering data points in multidimensional space is described. Each point has a neighborhood consisting of all points that are within a preset cutoff radius or distance. Each point is assigned a density measure based on the number of points in its neighborhood. Any point that has a higher density than any of its neighboring points is the centre of a cluster and is assigned a unique cluster ID. Every other point follows a path through the graph of neighboring points such that density is increasing as fast as possible until a cluster center is reached. The algorithm's performance is demonstrated on a one-dimensional, two-dimensional, and 18-dimensional dataset. | 01-10-2013 |
| 20120244577 | MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS - Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species. | 09-27-2012 |
| 20120149876 | Stable Heterodimeric Antibody Design with Mutations in the Fc Domain - The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics. | 06-14-2012 |
| 20110053261 | METHODS FOR DETERMINING CORRELATED RESIDUES IN A PROTEIN OR OTHER BIOPOLYMER USING MOLECULAR DYNAMICS - The invention provides methods and systems of determining biopolymer profiles and correlations between structural units (residues) of a biopolymer based on sampling of the conformational space available to the molecule. The correlations between these structural units can further be used to find networks within a biopolymer such as the coupled residue networks in a protein. The invention also provides for designing and engineering biopolymers including polypeptides, nucleic acids and carbohydrates using the information derived from the conformation clustering and subsequent methods described herein. | 03-03-2011 |
